Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00439244 · ClinicalTrials.gov registry record · Phase 3
Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 412
- Enrollment target
NCT00439244 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 412 participants.
The verdict
NCT00439244, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 412 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of zoledronic acid administered at the same time with teriparatide compared to zoledronic acid alone and teriparatide alone on bone mineral density (BMD) gain in the lumbar spine and total hip
Interventions
- DRUG Placebo
- DRUG Zoledronic acid
- DRUG Teriparatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 412 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00439244
The ClinicalTrials.gov registry entry for NCT00439244 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 412 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00439244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00439244 about?
NCT00439244 is a clinical study titled "Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis". The purpose of this study is to assess the effects of zoledronic acid administered at the same time with teriparatide compared to zoledronic acid alone and teriparatide alone on bone mineral density (BMD) gain in the lumbar spine and total hip
What is the current status of trial NCT00439244?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 412 participants. The study started on 2006-12. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00439244?
The interventions under investigation include: Placebo (DRUG), Zoledronic acid (DRUG), Teriparatide (DRUG).
Who is sponsoring clinical trial NCT00439244?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.